Chronic Kidney Disease(CKD)NCT06932042
PLADO for Conservative Management of CKD
A study testing PLADO and Standard-of-care diet in people with Chronic Kidney Disease(CKD) and Metabolic Acidosis, run by Lebanese American University at 1 site in Lebanon.
Trial summary
The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Kidney Disease(CKD), Metabolic Acidosis
- What is being tested?
- PLADO and Standard-of-care diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteLebanon
- Study dates
- 28 May 2024to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years and above, having controlled glycemic and blood pressure parameters on treatment, with an established diagnosis of stages 3-5 CKD and an estimated GFR ≤59 ml/min/1.73 m2 stable for at least three months, and with a normal nutritional status as defined by the GLIM criteria, attending the CKD outpatient clinics at LAUMC-RH, willing to undergo the baseline screening and attend the monthly face-to-face visits at the outpatient department at LAUMC-RH.
Who cannot join
- Patients with overt infection, persistent anorexia, vomiting, or diarrhea within the last month, presence of wasting diseases such as cancer, tuberculosis, liver failure, heart failure, and those with serum potassium >5.5 mEq/L during the past 6 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Lebanon1 site, 1 recruiting
- Recruiting
Lebanese American University Medical Center- Rizk Hospital
Beirut
Joelle Abi Kharma, +9611200800 ext. 3806, joelle.abikharma@lau.edu.lb
About this study
Official title: Plant Dominant Low-protein Diet for Conservative Management of Chronic Kidney Disease: A Randomized Controlled Trial
The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. It will also learn about the safety, viability, and economic attractiveness of this diet.
The main questions it aims to answer are:
Read more
- Is the PLADO diet more effective in managing metabolic acidosis in comparison with the standard-of-care CKD diet in adults with CKD?
- Is the PLADO diet safe, viable, and economically attractive adults with CKD?
Researchers will compare the PLADO diet to the standard-of-care CKD diet to see if the PLADO diet works better to decrease metabolic acidosis.
Participants will:
- Receive nutrition education of the PLADO diet or the standard-of-care CKD diet via monthly sessions for 6 months.
- Visit the clinic monthly for 6 months, then after 3 months for checkups and tests.
- Conditions
- Chronic Kidney Disease(CKD), Metabolic Acidosis
- Being tested
- PLADO, Standard-of-care diet
- Keywords
- Chronic kidney disease, metabolic acidosis, PLADO, Plant-dominant low protein diet, Nutrition education
- Medical subject headings
- Renal Insufficiency, Chronic, Acidosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PLADOOther
Low protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of <4 g/day and <3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance
Standard-of-care dietOther
Current standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences.
| Study group | Role | What they receive |
|---|---|---|
| PLADO | Experimental | Not described Receives: Other: PLADO |
| Standard-of-care diet | Active comparator | Not described Receives: Other: Standard-of-care diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolic acidosis assessed by PTCO2
Measured: Baseline, Monthly for 6 months, Month 9
Secondary outcomes (34)
Body weight
Body weight measured using a balance beam scale Unit: kg
Measured: Baseline, Months 3, 6, and 9
%Weight Change
%Weight Change (to the last measurement) Unit: %
Measured: Months 3, 6, and 9
Triceps Skinfold thickness
Triceps Skinfold thickness measured using a measuring tape and a skinfold caliper Unit: mm
Measured: Baseline, Months 3, 6, and 9
Body Fat Percentage
%Body Fat for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Measured: Baseline, Months 3, 6, and 9
Fat Free Mass Percentage
%Fat Free Mass for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Measured: Baseline, Months 3, 6, and 9
Total Body Water Percentage
%Total Body Water for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Measured: Baseline, Months 3, 6, and 9
Blood Urea Nitrogen (BUN)
BUN assessed via blood test Unit: mg/dL
Measured: Baseline, Monthly for 6 months, Month 9
Estimated Glomerular Filtration Rate (eGFR)
eGFR calculated using the Cockcroft-Gault equation = (((140 - age in years) x (weight in kg)) x 1.23) / (serum creatinine in micromol/l) Unit: mL/min/1.73m²
Measured: Baseline, Monthly for 6 months, Month 9
Serum Potassium (K)
Serum K assessed via blood test Unit: mEq/L
Measured: Baseline, Monthly for 6 months, Month 9
Serum Phosphorus (P)
Serum P assessed via blood test Unit: mg/dL
Measured: Baseline, Monthly for 6 months, Month 9
C-Reactive Protein (CRP)
Serum CRP assessed via blood test Unit: mg/L
Measured: Baseline, Months 3, 6, and 9
Albumin
Serum Albumin assessed via blood test Unit: g/dL
Measured: Baseline, Months 3, 6, and 9
Hemoglobin
Serum Hemoglobin assessed via blood test Unit: g/dL
Measured: Baseline, Months 3, 6, and 9
Hematocrit
Serum Hematocrit assessed via blood test Unit: %
Measured: Baseline, Months 3, 6, and 9
Mean Corpusculum Volume (MCV)
Average size of red blood cells assessed via blood test Unit: Femtoliter (fL)
Measured: Baseline, Months 3, 6, and 9
Ferritin
Serum Ferritin assessed via blood test Unit: ng/mL
Measured: Baseline, Months 3, 6, and 9
Glycated hemoglobin A1C
Glycated hemoglobin (A1C) measured via blood test Unit: %
Measured: Baseline, Months 3, 6, and 9
Urinary microalbumin: creatinine ratio (UmACR)
UmACR assessed via urine test Unit: mg/g creatinine
Measured: Baseline, Months 3, 6, and 9
Urinary potassium excretion
Urinary potassium excretion (spot) measured via urine test Unit: meq/L
Measured: Baseline, Months 3, 6, and 9
Urinary phosphorus excretion
Urinary phosphorus excretion (spot) measured via urine test Unit: mg/dL
Measured: Baseline, Months 3, 6, and 9
Global Leadership Initiative on Malnutrition (GLIM) criteria
GLIM criteria for the diagnosis of malnutrition. A participant is identified as malnourished when at least one phenotypic and one etiologic criterion is met. Phenotypic criteria include unintentional weight loss (>5% within 6 months or >10% beyond 6 months), age-specific low Body Mass Index (< 20 kg/m2 for individuals < 70 years old and < 22 kg/m2 for individuals 70 years and older), and reduced muscle mass assessed using body composition parameters to detect muscle depletion. Etiologic criteria include reduced food intake or assimilation (defined as a reduction in energy intake > 50% of requirements for over one week or any reduction lasting more than 2 weeks) and the presence of acute disease or chronic diseases related inflammation.
Score: one phenotypic criterion and one etiologic criterion, to diagnose malnutrition
Measured: Baseline, Months 3, 6, and 9
Total Caloric intake per kilogram body weight (Kcal/kg)
The total caloric intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total caloric intake (Kcal) will then be divided by the body weight (kg) at the same time point of data collection.
Unit: Kcal/kg
Measured: Baseline, Months 3, 6, and 9
Total dietary protein intake per kilogram body weight (g/kg)
The total dietary protein intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of dietary proteins in grams (g) will then be divided by the dry body weight (kg) at the same time point of data collection.
Unit: g/kg
Measured: Baseline, Months 3, 6, and 9
Carbohydrate intake percentage (%)
The total carbohydrate intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of carbohydrate in grams (g) will then be multiplied by 4 Kcal to get the calories of carbohydrates. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.
Unit: percentage (%)
Measured: Baseline, Months 3, 6, and 9
Total fat intake percentage (%)
The total fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.
Unit: percentage (%)
Measured: Baseline, Months 3, 6, and 9
Trans fat intake percentage (%)
The total trans-fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of trans-fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.
Unit: percentage (%)
Measured: Baseline, Months 3, 6, and 9
Total potassium intake (g)
The total potassium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.
Unit: g/d
Measured: Baseline, Months 3, 6, and 9
Total phosphorus intake (g)
The total phosphorus intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.
Unit: g/d
Measured: Baseline, Months 3, 6, and 9
Total sodium intake (g)
The total sodium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.
Unit: g/d
Measured: Baseline, Months 3, 6, and 9
Nutrition focused physical examination (NFPE)
The nutrition focused physical examination will be conducted by a licensed dietitian who will assess fat and muscle depletion, as well as the presence of edema.
Measured: Baseline, Months 3, 6, and 9
Muscle strength (kg)
Muscle strength will be measured using a handgrip strength assessment with a calibrated hand dynamometer. Participants will be seated upright with their back supported, feet flat on the floor, and their elbow flexed at a 90-degree angle. The hand dynamometer will be adjusted to fit the participant's hand size who will be instructed to squeeze the dynamometer with maximum effort for 3-5 seconds. Three measurements will be taken for each hand, with a rest period of 30 to 60 seconds and the average of the three measurements will be recorded as the final handgrip strength.
Unit: kg
Measured: Baseline, Months 3, 6, and 9
Gastrointestinal Symptoms
Gastrointestinal symptoms will be assessed using the Birmingham IBS Symptom Questionnaire (B-IBS-Q), a validated tool for evaluating the frequency, severity, and impact of gastrointestinal symptoms. It is a self-administered questionnaire consisting of 11 items designed to assess the frequency of IBS-related symptoms, with each question having a standard response scale. Symptoms are measured based on a 6-point Likert scale (0-5) ranging from all of the time (5) to none (0) and converted to 100, with higher scores indicating more frequent IBS symptoms. The scale has 3 dimensions, including pain, constipation, and diarrhea.
Measured: Baseline, Monthly for 6 months, Month 9
Health-related Quality of Life
Quality of life will be assessed using the EuroQOL-5D-5L (EQ-5D-5L), a widely validated and internationally recognized instrument for measuring health-related quality of life. The tool consists of two components: a descriptive system and a visual analog scale (VAS). The descriptive component includes five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale, ranging from no problems to extreme problems. Participants will select the most appropriate level that reflects their current health status for each dimension. The responses are then used to generate a health state profile, which can be converted into a single index score using country-specific value sets. In addition to the descriptive system, participants will rate their overall health status using a visual analog scale (VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health).
Measured: Baseline, Months 3, 6, and 9
Costs
Costs relevant to direct medical costs, direct non-medical costs, and indirect costs assessed using a resource utilization questionnaire with the patients, and calculated following the identification, measurement, and valuation steps.
Measured: Baseline, Months 3, 6, and 9
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start28 May 2024
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney Disease(CKD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lebanese American University
- Sponsor type
- University, hospital or other
- Collaborators
- Zayed University, Maastricht University
- Responsible party
- Principal investigator, Rana Rizk, Lebanese American University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06932042
- Sponsor's protocol ID
- LAU.SAS.RR4.2/Feb/2024
- Status last verified
- Apr 2025
- First submitted
- 1 Apr 2025
- Last updated
- 17 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kharma JA, Sultan R, Rizk R, Haroun D, Kilani H, Kalantar-Zadeh K, Gubbels J, Bessems K. Plant-dominant low-protein diet versus standard care in adults with chronic kidney disease stages 3-5: A randomized controlled trial protocol. Nutr Res. 2026 Jul;151:1-15. doi: 10.1016/j.nutres.2026.04.004. Epub 2026 Apr 22.
PubMed 42155424
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Plant Dominant Low-protein Diet for Conservative Management of Chronic Kidney Disease: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06932042
- Acronym / sponsor ID
- LAU.SAS.RR4.2/Feb/2024
- Conditions
- Chronic Kidney Disease(CKD), Metabolic Acidosis
- Keywords
- Chronic kidney disease, metabolic acidosis, PLADO, Plant-dominant low protein diet, Nutrition education
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Lebanese American UniversityUniversity, hospital or other
- Collaborators
- Zayed University, Maastricht University
- Study start
- 28 May 2024 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. It will also learn about the safety, viability, and economic attractiveness of this diet.
The main questions it aims to answer are:
- Is the PLADO diet more effective in managing metabolic acidosis in comparison with the standard-of-care CKD diet in adults with CKD?
- Is the PLADO diet safe, viable, and economically attractive adults with CKD?
Researchers will compare the PLADO diet to the standard-of-care CKD diet to see if the PLADO diet works better to decrease metabolic acidosis.
Participants will:
- Receive nutrition education of the PLADO diet or the standard-of-care CKD diet via monthly sessions for 6 months.
- Visit the clinic monthly for 6 months, then after 3 months for checkups and tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PLADO | Experimental | Other: PLADO |
| Standard-of-care diet | Active comparator | Other: Standard-of-care diet |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients aged 18 years and above, having controlled glycemic and blood pressure parameters on treatment, with an established diagnosis of stages 3-5 CKD and an estimated GFR ≤59 ml/min/1.73 m2 stable for at least three months, and with a normal nutritional status as defined by the GLIM criteria, attending the CKD outpatient clinics at LAUMC-RH, willing to undergo the baseline screening and attend the monthly face-to-face visits at the outpatient department at LAUMC-RH.
Key exclusion criteria (1 listed)
- Patients with overt infection, persistent anorexia, vomiting, or diarrhea within the last month, presence of wasting diseases such as cancer, tuberculosis, liver failure, heart failure, and those with serum potassium >5.5 mEq/L during the past 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PLADOLow protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of <4 g/day and <3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance | Other | PLADO |
| Standard-of-care dietCurrent standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences. | Other | Standard-of-care diet |
Primary outcome
Metabolic acidosis assessed by PTCO2
Time frame: Baseline, Monthly for 6 months, Month 9
34 secondary outcomes
Body weight
Time frame: Baseline, Months 3, 6, and 9
%Weight Change
Time frame: Months 3, 6, and 9
Triceps Skinfold thickness
Time frame: Baseline, Months 3, 6, and 9
Body Fat Percentage
Time frame: Baseline, Months 3, 6, and 9
Fat Free Mass Percentage
Time frame: Baseline, Months 3, 6, and 9
Total Body Water Percentage
Time frame: Baseline, Months 3, 6, and 9
Blood Urea Nitrogen (BUN)
Time frame: Baseline, Monthly for 6 months, Month 9
Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Monthly for 6 months, Month 9
Serum Potassium (K)
Time frame: Baseline, Monthly for 6 months, Month 9
Serum Phosphorus (P)
Time frame: Baseline, Monthly for 6 months, Month 9
C-Reactive Protein (CRP)
Time frame: Baseline, Months 3, 6, and 9
Albumin
Time frame: Baseline, Months 3, 6, and 9
Hemoglobin
Time frame: Baseline, Months 3, 6, and 9
Hematocrit
Time frame: Baseline, Months 3, 6, and 9
Mean Corpusculum Volume (MCV)
Time frame: Baseline, Months 3, 6, and 9
Ferritin
Time frame: Baseline, Months 3, 6, and 9
Glycated hemoglobin A1C
Time frame: Baseline, Months 3, 6, and 9
Urinary microalbumin: creatinine ratio (UmACR)
Time frame: Baseline, Months 3, 6, and 9
Urinary potassium excretion
Time frame: Baseline, Months 3, 6, and 9
Urinary phosphorus excretion
Time frame: Baseline, Months 3, 6, and 9
Global Leadership Initiative on Malnutrition (GLIM) criteria
Time frame: Baseline, Months 3, 6, and 9
Total Caloric intake per kilogram body weight (Kcal/kg)
Time frame: Baseline, Months 3, 6, and 9
Total dietary protein intake per kilogram body weight (g/kg)
Time frame: Baseline, Months 3, 6, and 9
Carbohydrate intake percentage (%)
Time frame: Baseline, Months 3, 6, and 9
Total fat intake percentage (%)
Time frame: Baseline, Months 3, 6, and 9
Trans fat intake percentage (%)
Time frame: Baseline, Months 3, 6, and 9
Total potassium intake (g)
Time frame: Baseline, Months 3, 6, and 9
Total phosphorus intake (g)
Time frame: Baseline, Months 3, 6, and 9
Total sodium intake (g)
Time frame: Baseline, Months 3, 6, and 9
Nutrition focused physical examination (NFPE)
Time frame: Baseline, Months 3, 6, and 9
Muscle strength (kg)
Time frame: Baseline, Months 3, 6, and 9
Gastrointestinal Symptoms
Time frame: Baseline, Monthly for 6 months, Month 9
Health-related Quality of Life
Time frame: Baseline, Months 3, 6, and 9
Costs
Time frame: Baseline, Months 3, 6, and 9
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2025.
- Derived from this study: PubMed 42155424Kharma JA, Sultan R, Rizk R, Haroun D, Kilani H, Kalantar-Zadeh K, Gubbels J, Bessems K. Plant-dominant low-protein diet versus standard care in adults with chronic kidney disease stages 3-5: A randomized controlled trial protocol. Nutr Res. 2026 Jul;151:1-15. doi: 10.1016/j.nutres.2026.04.004. Epub 2026 Apr 22.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease(CKD)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
RecruitingObservational study
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PLADO and Standard-of-care diet in people with Chronic Kidney Disease(CKD) and Metabolic Acidosis, run by Lebanese American University at 1 site in Lebanon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rana Rizk, PhD, MS, MPH, LD (+9611786456 ext. 3741, rana.rizk01@lau.edu.lb), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolic acidosis assessed by PTCO2 (time frame: Baseline, Monthly for 6 months, Month 9). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06932042, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2025.